
Follow-up roadmap nuclear drug development: concretising and prioritising
Follow-up roadmap nuclear drug development: concretising and prioritising
On 11 June, thirteen stakeholders from the field of nuclear medicine development met in an Acceleration Room organised by FAST. This meeting was a follow-up to the “Nuclear Medicine Development” roadmap and aimed to: jointly formulate concrete, shared actions – small or large – that contribute to realising the ambition to explore.
Gaining insight into logical or necessary starting points for follow-up steps
The “Nuclear Medicine Development” roadmap drawn up by quartermaster Wim Oyen served as a basis. The Acceleration Chamber set to work on translating the shared ambition, ‘Dutch nuclear medicine development is world-leading and leads to broad patient access to new treatment perspectives’, into concrete and specific objectives and setting priorities to achieve further progress.
Nice steps have been taken, the assessment of the goals showed that education and public-private cooperation in particular are seen as top priorities. Participants stressed that direction is needed to avoid fragmentation and that there are several goals that can be clustered thematically.
There will be an update on the follow-up at the FAST Event on 4 November 2025: ‘Innovation and affordability go hand in hand. Register now for the FAST Event and join the radiopharmaceutical afternoon session.
